Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That's slimly hopeful.
That’s great growth news especially if there are rec legal initiatives in the state, otherwise the entire market is about 28,000 registered patients.
The one of only two vertical licenses is a coup.
I hope they didn’t overpay?
A new challenge is coming from Big Pharma --->>> Teva Israel enters medical cannabis market with new partnership
Reuters
https://www.reuters.com/world/middle-east/teva-pharm-enters-medical-cannabis-market-with-new-partnership-2021-12-26/
JERUSALEM, Dec 26 (Reuters) - (This December 26 story was corrected after company clarified that the deal is with Teva Israel)
The Israeli unit of drugmaker Teva Pharmaceutical Industries (TEVA.TA) said on Sunday it was entering the medical cannabis market by signing an exclusive and mutual collaboration agreement with another Israeli company, Tikun Olam-Cannbit (TKUN.TA).
Under the agreement, Tikun Olam-Cannbit will produce several medical cannabis products that are administered as oils. They will be marketed by Teva Israel to patients in Israel, the Palestinian Authority and, when the market opens, Ukraine, the company said.
Once Teva Israel receives all the required regulatory approvals, the companies will collaborate for 10 years and that could be extended by another nine years.
"Today, it is clear to many in the pharmaceutical industry and in the medical community that use of oils produced from specific cannabis strains may provide additional treatment options and respond to unaddressed medical needs of patients," said Yossi Ofek, chief executive of Teva Israel.
Big Pharma competition is coming --->>> Teva Israel enters medical cannabis market with new partnership
Reuters
https://www.reuters.com/world/middle-east/teva-pharm-enters-medical-cannabis-market-with-new-partnership-2021-12-26/
JERUSALEM, Dec 26 (Reuters) - (This December 26 story was corrected after company clarified that the deal is with Teva Israel)
The Israeli unit of drugmaker Teva Pharmaceutical Industries (TEVA.TA) said on Sunday it was entering the medical cannabis market by signing an exclusive and mutual collaboration agreement with another Israeli company, Tikun Olam-Cannbit (TKUN.TA).
Under the agreement, Tikun Olam-Cannbit will produce several medical cannabis products that are administered as oils. They will be marketed by Teva Israel to patients in Israel, the Palestinian Authority and, when the market opens, Ukraine, the company said.
Once Teva Israel receives all the required regulatory approvals, the companies will collaborate for 10 years and that could be extended by another nine years.
"Today, it is clear to many in the pharmaceutical industry and in the medical community that use of oils produced from specific cannabis strains may provide additional treatment options and respond to unaddressed medical needs of patients," said Yossi Ofek, chief executive of Teva Israel.
Big Pharma competition is coming --->>> Teva Israel enters medical cannabis market with new partnership
Reuters
https://www.reuters.com/world/middle-east/teva-pharm-enters-medical-cannabis-market-with-new-partnership-2021-12-26/
JERUSALEM, Dec 26 (Reuters) - (This December 26 story was corrected after company clarified that the deal is with Teva Israel)
The Israeli unit of drugmaker Teva Pharmaceutical Industries (TEVA.TA) said on Sunday it was entering the medical cannabis market by signing an exclusive and mutual collaboration agreement with another Israeli company, Tikun Olam-Cannbit (TKUN.TA).
Under the agreement, Tikun Olam-Cannbit will produce several medical cannabis products that are administered as oils. They will be marketed by Teva Israel to patients in Israel, the Palestinian Authority and, when the market opens, Ukraine, the company said.
Once Teva Israel receives all the required regulatory approvals, the companies will collaborate for 10 years and that could be extended by another nine years.
"Today, it is clear to many in the pharmaceutical industry and in the medical community that use of oils produced from specific cannabis strains may provide additional treatment options and respond to unaddressed medical needs of patients," said Yossi Ofek, chief executive of Teva Israel.
Teva Israel enters medical cannabis market with new partnership
Reuters
https://www.reuters.com/world/middle-east/teva-pharm-enters-medical-cannabis-market-with-new-partnership-2021-12-26/
JERUSALEM, Dec 26 (Reuters) - (This December 26 story was corrected after company clarified that the deal is with Teva Israel)
The Israeli unit of drugmaker Teva Pharmaceutical Industries (TEVA.TA) said on Sunday it was entering the medical cannabis market by signing an exclusive and mutual collaboration agreement with another Israeli company, Tikun Olam-Cannbit (TKUN.TA).
Under the agreement, Tikun Olam-Cannbit will produce several medical cannabis products that are administered as oils. They will be marketed by Teva Israel to patients in Israel, the Palestinian Authority and, when the market opens, Ukraine, the company said.
Once Teva Israel receives all the required regulatory approvals, the companies will collaborate for 10 years and that could be extended by another nine years.
"Today, it is clear to many in the pharmaceutical industry and in the medical community that use of oils produced from specific cannabis strains may provide additional treatment options and respond to unaddressed medical needs of patients," said Yossi Ofek, chief executive of Teva Israel.
Don’t worry about turning me on to ODYY.
I looked up Phase 1 trials regarding typical length. We’re in this for at least until October 2022.
The trial will only stop in the near term if participants have adverse effects from taking the drug.
That’s hilarious small world stuff.
Is 5¢ next?--->>>Aleafia Health Announces Closing of a New $19 Million Credit Facility and Extension of Existing Credit Facility
• Credit Facility provides the Company with liquidity to fund operations and organic growth initiatives --->>> What a shame. This isn't money for growth. It's money to keep the lights on. - FUNMAN
• Two-year term provides additional financial flexibility
TORONTO – December 29, 2021 – Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia Health” or the “Company”) is pleased to announce the closing of a credit facility of up to $19 million (the “Credit Facility”).
“This financing improves our liquidity and capital structure as the Company’s senior secured debt obligations will now mature in December 2023 rather than in August 2022,” said Aleafia Health CEO Geoffrey Benic. “The transaction allows us to continue the growth of our core adult-use and medical cannabis sales channels, as we again expect to realize sequential growth in both channels over the previous quarter.”
The Credit Facility is financed by the Garrington Group of Companies, a Toronto-based private lender providing working capital financing to the underserved, small to mid-sized middle market sector across North America, providing credit facilities that generally range from $1 million to over $30 million. It consists of a revolving receivables facility of up to $7 million and a term loan of $12 million. The maturity date is December 2023. The term loan was fully drawn by the Company upon closing. The revolving receivables facility is expected to be drawn in January 2022 and further thereafter as receivables grow with the Company’s revenue. The interest rate is in-line with the Company’s existing credit facility and is payable monthly. The Credit Facility is secured primarily by way of first lien mortgages on the Company’s Paris, Ontario and Grimsby, Ontario production facilities, and includes customary financial and restrictive covenants. The net proceeds from the Credit Facility will be used to fund working capital, to repay $5 million in principal on the existing senior secured credit facility, announced on August 23, 2021 (the “August Credit Facility”), along with accrued interest and fees, and for general corporate purposes.
The term of the August Credit Facility has been extended from August 2022 to December 2023. In connection with that facility, a first lien mortgage will be granted on the Company’s Port Perry, Ontario outdoor cultivation property.
For Investor & Media Relations:
1-833-879-2533
IR@AleafiaHealth.com
LEARN MORE: www.AleafiaHealth.com
About Aleafia Health:
Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada. The Company has developed an international footprint, with subsidiaries or investments in German and Australian medical cannabis companies and has products available in both markets.
The Company owns and operates a virtual network of medical cannabis clinics staffed by physicians and nurse practitioners who have seen over 75,000 patients to date.
Aleafia Health owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the first large-scale, legal outdoor cultivation facility in Canadian history. The Company produces a diverse portfolio of cannabis derivative products including oils, capsules, edibles, sublingual strips, and vapes, for sale in Canada in the medical and adult-use markets, and in select international jurisdictions.
Forward Looking Information
This news release contains forward-looking information within the meaning of applicable Canadian and United States securities laws. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, or “believes” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including risks contained in the Company’s annual information form filed with Canadian securities regulators available on the Company’s SEDAR profile at www.sedar.com.
Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company does not undertake any obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
I wonder how much time is needed for the phase 1 trial?
They announced they started enrolling people on Sept 22, 2021.
Does it seem reasonable that there might not be any results for at least a year?
Phase 1: These trials usually enroll 20 to 100 healthy volunteers or people with the condition being studied, and last several months. This phase measures safety by testing for any adverse side effects of the treatment, but not necessarily how effective the drug or device is.
I repeat, it really seems impossible to test. How can they keep finding people who just had concussion trauma?
Trulieve Expands Executive Leadership Team
December 28, 2021 at 9:38 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-expands-executive-leadership-team
Steve White named President after Harvest acquisition
TALLAHASSEE, FL, Dec. 28, 2021 /CNW/ - Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today announced several new executive appointments including; President, Steve White; Vice President & General Counsel, Nicole Stanton; Director of Investor Relations, Christine Hersey; and Executive Director of Corporate Communications, Rob Kremer.
The White, Stanton and Hersey appointments follow the Company's October 1, 2021, closing of the acquisition of Harvest Health and Recreation Inc. ("Harvest").
"We are thrilled to officially announce the appointment of several members of the legacy Harvest team to key roles within our organization," said Kim Rivers, Trulieve's Chief Executive Officer. "The addition of talent and experienced leadership was a key component of the Harvest acquisition and further advances our strategy of expansion through the addition of regional assets and teams within our hub model. We also are adding to our leadership team as the company continues to experience significant growth."
These leaders deliver a breadth of experience from multiple industries to Trulieve's leadership team:
Steve White, President – Mr. White co-founded Harvest Health & Recreation in 2011 and served as Chief Executive Officer until the acquisition of the company by Trulieve. As an early pioneer in the U.S. legal cannabis industry, Mr. White led the company as it grew from a single dispensary to become one of the top multi-state operators with cultivation, manufacturing, and retail operations in several markets. Mr. White spearheaded one of the industry's most successful license application teams, paving the way for rapid growth through organic license awards and capital efficient expansion. As a former litigator, Steve White successfully navigated the complex patchwork of different regulatory regimes across various U.S. markets while advocating for expanded access to cannabis for patients and adult use consumers. Steve White serves as a member of the boards of the Arizona Dispensary Association and charitable organization Harvesting Hope. Mr. White graduated from Arizona State University Honors College summa cum laude with a B.S. in Political Science and earned a Juris Doctorate from Washington & Lee University, School of Law.
Nicole Stanton, Vice President and General Counsel – Ms. Stanton served as Vice President, General Counsel and Secretary of Harvest since 2019, overseeing the legal department and compliance program. She received the Public Company General Counsel of the Year award by the Arizona Corporate Counsel in April 2021. That same year, the Harvest legal department was nominated for Legal Department of the Year. Prior to joining Harvest, Ms. Stanton was employed by the national law firm of Quarles & Brady LLP for nearly 20 years. She served as the office managing partner of the firm's Phoenix office from 2013-2018, as well as the firm's assistant general counsel from 2009-2019. While managing partner, she was responsible for overseeing more than 100 lawyers and 75 professional legal staff, covering 11 different legal practice areas. She is a veteran litigation and legal ethics counsel. Her success as defense counsel garnered her an established and credible reputation across business practices including awards as one of the Top 100 Lawyers in Arizona from AZ Business Magazine (2015-2108) and Phoenix Business Journal's Most Admired Leaders (2014). Ms. Stanton holds a Bachelor of Science in Communication from the University of Utah and a Juris Doctorate from the University of Arizona, College of Law. She has taught legal ethics at Arizona State University's Sandra Day O'Connor College of Law and is a member of the prestigious American Law Institute.
Christine Hersey, Director of Investor Relations – Ms. Hersey served as Director of Investor Relations at Harvest since June 2019. She has over 20 years' experience in corporate, buy-side and sell side roles working in and covering a variety of sectors including biotech, cannabis, cleantech, and consumer retail at Durant Partners, Efficacy Capital, M.S. Howells, Savitr Capital, and Wedbush Securities. Ms. Hersey previously covered global securities traveling throughout the U.S., Europe and Asia. Prior to her career in finance, Christine worked as an environmental engineer and project manager. Ms. Hersey earned a B.S. in Civil Engineering from Worcester Polytechnic Institute, M.S. in Civil Engineering from Northeastern University, and an MBA and M.S. in Finance from Boston College.
Rob Kremer, Executive Director of Corporate Communications – Mr. Kremer has nearly 30 years of experience in both corporate and agency settings. In his role at Trulieve, he will oversee both internal and external communications. Kremer spent the past 10 years as a partner at Rhythm Communications where he developed and implemented successful programs and campaigns. Client leadership includes Chick-fil-A, General Mills, Mizuno, as well as celebrities such as Champ Bailey, Ludacris and Ray Lewis, among many others. Previously, he served as in-house PR at both Coca-Cola and Aetna U.S. Healthcare, as well as an internal communications consultant at Hewitt Associates. Several campaigns under his stewardship have been recognized for regional and national awards. Mr. Kremer is a graduate of the Henry W. Grady School of Journalism at the University of Georgia and serves on numerous philanthropic boards.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
SOURCE Trulieve Cannabis Corp.
That's the way the party in power gets things done. They get sworn in a presto, it hits the front burner.
Watch --->>> Fire & Flower: We are celebrating our 100th store! Just like you, we’ve always enjoyed cannabis and believe it should be as simple as it is enjoyable. Whether you're a long-time veteran or just canna-curious we're happy to be there for you.
Link in bio for all our locations and don't forget to stop by for Boxing Week ??
https://www.facebook.com/fireandflowerco/videos/5048122941886404
Trulieve to Open Port Richey, Florida Dispensary on Thursday, December 23
Fire & Flower has a 221.5 per cent upside, says PI Financial
PI Financial analyst Jason Zandberg believes there’s smoke with Fire & Flower (Fire and Flower Stock Quote, Chart, News TSX:FAF), initiating coverage on December 9 with a “Buy” rating and target price of $20/share for a projected return of 221.5 per cent.
Founded in 2017 and headquartered in Toronto, Fire & Flower Holdings is an independent retailer of cannabis products and accessories through its 82 locations in Alberta, Manitoba, Ontario, Yukon and Saskatchewan, where the company also engages in the wholesale of regulated cannabis products and accessories. The company also has a proprietary cannabis retail and analytics platform Hifyre.
“We believe that FAF is undervalued as a cannabis retailer and very little value has been attributed to its cannabis retailing technology — Hifyre,” Zandberg said. “We feel Hifyre could be worth more than its retail stores.”
Originally known as Cinaport Acquisition Corp. II, Fire & Flower began trading on the TSX Venture Exchange in February 2019 and was rapidly expanding its retail footprint through a combination of acquisitions and organic store openings. A year into its public tenure, the company entered into an agreement with American Acres to license its Fire & Flower brand, store operating system and Hifyre technology platform for dispensaries in California, Arizona and Nevada.
In August, the company officially rebranded as Fire & Flower Holdings and opened its first branded store in Palm Springs, California.
Zandberg’s hype around the Hifyre business particularly revolves around its proprietary technology stack, called Hifyre IQ, that the analyst sees as giving Fire & Flower a competitive advantage in retail, as well as the ability to license the technology to provide a high-margin source of revenue. The system captures user behaviour data and applies predictive analytics to facilitate the retail business’ delivery of a personalized customer experience.
“The most exciting part about Hifyre is the company’s ability to generate highly profitable revenue by licensing the technology stack they have developed,” Zandberg said. “The platform has a wide list of customers including licensed producers, traditional CPG companies, government organizations and financial institutions.”
The Hifyre portfolio also includes Hifyre Reach, a digital advertising and retail media network offering for licensed producers, and Hifyre One, an online digital interface for cannabis dispensaries and branded e-commerce sites for licensed producers.
Since the release of Zandberg’s initiation, Fire & Flower also secured an additional $30 million debt facility from Alimentation Couche-Tard, a 22.4 per cent stakeholder in the company with options to increase ownership to a majority stake at 50.1 per cent, as well as being the second largest convenience store retailer in North America.
“Access to $30 million of non-dilutive debt financing is a strong show of support from our partner, Alimentation Couche-Tard. It also serves as a proof point on our alignment towards the future of cannabis retail,” said Trevor Fencott, Chief Executive Officer of Fire & Flower in the company’s December 13 press release. “Through their leadership, network and expertise, we are accelerating the dynamics of the retail shopping experience and creating a consumer-centric marketplace that leverages technology and data-driven insights to deliver a personalised collection of products to consumers and reaches them wherever they are at.”
Zandberg expects Fire & Flower’s financial picture to take greater root moving forward, projecting a jump to $184 million in revenue for 2021 for a potential year-over-year increase of 43.8 per cent, followed by a jump to a projected $227 million in 2022 for a potential year-over-year increase of 23.4 per cent, punctuated by a forecasted jump to $289 million in 2023 for a potential year-over-year increase of 27.3 per cent.
Looking at valuation, Zandberg projects the company’s EV/Revenue multiple to drop from the reported 3.1x in 2020 to a projected 2.1x in 2021, then dropping to a projected 1.7x in 2022 and 1.4x in 2023.
Meanwhile, after a reported loss of $14 million in 2020, Zandberg projects the company’s adjusted EBITDA to turn positive at $13 million for a margin of 7.1 per cent, with a projected increase to $25 million and a margin of 11 per cent in 2022, with a further expansion to a projected $47 million and margin of 16.3 per cent in play for 2023.
With the move to a positive adjusted EBITDA, Zandberg introduces the EV/EBITDA multiple in his 2021 forecast at 30.5x, then dropping to a projected 15.8x in 2022 and 8.4x in 2023.
Zandberg also projects the company to turn a positive EPS beginning in 2023 at $0.25/share; he also brings in a P/E multiple that year at a projected 25.6x.
Fire & Flower’s share price has not blossomed much as of late, producing a loss of 38.6 per cent for the year to date, peaking at $14.50/share on February 22 and bottoming out at $5.07/share on December 3.
Very interesting to read that AOC is asking the president to move on cannabis legalization via executive orders.
It might be the only near term way to get it done.
The dems were shooting for the moon on every dream program their splintered party could fantasize about. They are so bad at legislating that they may even screw up cannabis legalization, even when about 70% of America approves of cannabis legalization. That's how bad the dems are at politicking and acting as a unified bloc.
They have a public super majority and still might not get legalization done.
Tennessee Gas Pipeline Announces New Responsibly Sourced Natural Gas Supply Aggregation Pooling Service
First to offer service and further demonstrates commitment to lower-carbon future
12/15/2021
https://ir.kindermorgan.com/news/news-details/2021/Tennessee-Gas-Pipeline-Announces-New-Responsibly-Sourced-Natural-Gas-Supply-Aggregation-Pooling-Service/default.aspx
HOUSTON--(BUSINESS WIRE)-- Tennessee Gas Pipeline (TGP), a subsidiary of Kinder Morgan, Inc. (NYSE: KMI) today filed with the Federal Energy Regulatory Commission (FERC) a proposal to implement a responsibly sourced natural gas (RSG) supply aggregation pooling service at select locations across the TGP system.
RSG is third-party certified natural gas that meets certain environmental, social and governance standards, particularly related to methane emission reductions.
The proposed service is designed to enable suppliers and customers on TGP to purchase and sell RSG supply at non-physical trading locations, ultimately serving end-users, utilities, power plants and LNG facilities connected to the TGP system. Producers who have already obtained RSG certifications from qualified third-party organizations are anticipated to supply the RSG needed for the proposed pooling service, and the supply is expected to grow as RSG becomes the fuel of choice among customers.
Pending regulatory approval from the FERC, this service is expected to be available in the first quarter of 2022.
“We are pleased that TGP is the first pipeline system to offer this RSG supply aggregation pooling service,” said TGP’s Vice President of Commercial Ernesto Ochoa. “We believe this lower methane intensity fuel is an essential component of the energy transition, and TGP is uniquely positioned to be the transporter of choice because of its connectivity to key basins and end-users. We are excited to continue to work with current and future customers to encourage the delivery of RSG supply into our systems and pursue new ways to facilitate the availability of these molecules to the market.”
About Kinder Morgan, Inc.
Kinder Morgan, Inc. (NYSE: KMI) is one of the largest energy infrastructure companies in North America. Access to reliable, affordable energy is a critical component for improving lives around the world. We are committed to providing energy transportation and storage services in a safe, efficient, and environmentally responsible manner for the benefit of people, communities and businesses we serve. We own an interest in or operate approximately 83,000 miles of pipelines and 144 terminals. Our pipelines transport natural gas, renewable fuels, refined petroleum products, crude oil, condensate, CO2 and other products, and our terminals store and handle various commodities including gasoline, diesel fuel, chemicals, ethanol, metals and petroleum coke. Learn more about our renewables initiatives on the low carbon solutions page at www.kindermorgan.com.
Important Information Relating to Forward-Looking Statements
This news release includes forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities and Exchange Act of 1934. Generally the words “expects,” “believes,” anticipates,” “plans,” “will,” “shall,” “estimates,” and similar expressions identify forward-looking statements, which are not historical in nature. Forward-looking statements in this news release include express or implied statements concerning demand for RSG and the anticipated timing and benefits of the proposed RSG pooling program. Forward-looking statements are subject to risks and uncertainties and are based on the beliefs and assumptions of management, based on information currently available to them. Although KMI believes that these forward-looking statements are based on reasonable assumptions, it can give no assurance as to when or if any such forward-looking statements will materialize or their ultimate impact on KMI’s operations or financial condition. Important factors that could cause actual results to differ materially from those expressed in or implied by these forward-looking statements include the risks and uncertainties described in KMI’s reports filed with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year-ended December 31, 2020 (under the headings “Risk Factors” and “Information Regarding Forward-Looking Statements” and elsewhere) and its subsequent reports, which are available through the SEC’s EDGAR system at www.sec.gov and on KMI’s website at ir.kindermorgan.com.
Katherine Hill
Senior Corporate Communications Specialist
(713) 469-9176
newsroom@kindermorgan.com
Investor Relations
(800) 348-7320
km_ir@kindermorgan.com
www.kindermorgan.com
Source: Kinder Morgan, Inc.
CVS Health to present at the 40th Annual J.P. Morgan Healthcare Conference
Wednesday, December 22, 2021
https://cvshealth.com/news-and-insights/press-releases/cvs-health-to-present-at-the-40th-annual-jp-morgan-healthcare
WOONSOCKET, R.I. — CVS Health® (NYSE: CVS) today announced that President and CEO Karen S. Lynch and Executive Vice President and Chief Financial Officer Shawn Guertin will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at approximately 8:15 am ET.
About CVS Health
CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and approximately 300,000 dedicated colleagues including more than 40,000 physicians, pharmacists, nurses, and nurse practitioners. Wherever and whenever people need us, we help them with their health whether that's managing chronic diseases, staying compliant with their medications, or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system and their personal health care by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Learn more at www.cvshealth.com.
Media Contact
T.J. Crawford
212-457-0583
CrawfordT2@cvshealth.com
Investor contact
Susie Lisa, CFA
401-770-4050
Susan.Lisa@cvshealth.com
Cresco Labs Announces Opening of 45th Nationwide Dispensary in Sarasota, FL
December 17, 2021
https://investors.crescolabs.com/investors/press-releases/press-release-details/2021/Cresco-Labs-Announces-Opening-of-45th-Nationwide-Dispensary-in-Sarasota-FL/default.aspx
CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, is expanding its Sunnyside brand in southwest Florida with a new store located at 8307 Lockwood Ridge Rd. in Sarasota. Sunnyside Sarasota marks Cresco Labs’ 13th Florida location and 45th nationwide store.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211217005060/en/
“We are excited to open Sunnyside Sarasota to continue to expand access to our branded products for Florida patients,” said Charlie Bachtell, Cresco Labs’ CEO & Co-founder. “This is our fifth new dispensary since entering Florida in April, and we expect to continue to expand across the state in the New Year so more patients have access to our products, which have proven to be some of the most popular in other states.”
Sunnyside Sarasota is centrally located in the city between Interstate 75 and the Sarasota Bradenton International Airport. The store is in University Square Plaza, one of Sarasota’s busiest shopping areas. Sarasota is renowned for its cultural institutes, notably the Ringling Museum of Art. It’s also the gateway to miles of beaches, such as Lido Beach and Siesta Key Beach.
Registered patients with a medical card have the option to place orders online through the Sunnyside.shop website or utilize next-day delivery. Delivery orders can be placed in store or by phone at 877-395-1009. Patients can also visit Sunnyside Sarasota to speak with wellness advisors for purchasing assistance. Regular store hours are Monday through Saturday, 10 a.m. to 8 p.m., and Sunday, 10 a.m. to 5 p.m. For more information about Sunnyside, visit www.sunnyside.shop.
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.
Forward-Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211217005060/en/
Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
Investors:
investors@crescolabs.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
Source: Cresco Labs Inc.
Trulieve Expands Patient Access to Medical Cannabis with Eighth Tampa-area Dispensary
December 21, 2021 at 11:04 AM EST
https://investors.trulieve.com/news-releases/news-release-details/trulieve-expands-patient-access-medical-cannabis-eighth-tampa
Numerous grand opening specials available at new Tampa-Hillsborough location
TALLAHASSEE, Fla., Dec. 21, 2021 /PRNewswire/ - Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, today opens its eighth medical cannabis dispensary in the Tampa area. The Tampa-Fairgrounds Trulieve, located at 7702 E. Hillsborough Avenue near the intersection of I-4 and I-75, begins serving patients at 9am on Tuesday, December 21.
There will be deals and specials throughout opening day, including a 25% discount for all registered patients at the Tampa-Fairgrounds location. Grand opening festivities will include St. Petersburg-based Craft Tee custom t-shirt printing, music, and numerous partner giveaways. As always, all first-time guests are eligible for a 50% new customer discount at any Florida-based location. Trulieve also offers statewide home delivery, convenient online ordering, and in-store pickup.
Statewide on Tuesday, December 21, Trulieve will continue its 12 Days of Cannabis promotion with the launch of the TruChocolate Dark Chocolate Cranberry and special one-day deals on brand partner, Bhang's dark and milk chocolate edibles.
As the state's leading medical cannabis provider, Trulieve's retail employees are trained to provide personalized patient care and support individuals at every stage of their cannabis journey. Trulieve dispensaries throughout Florida offer on-site consultations to help patients obtain appropriate medical products and dosages to ensure optimal cannabis experiences.
"Trulieve is excited to expand access to medical cannabis in Tampa and to continue building strong relationships in the community," said Kim Rivers, CEO of Trulieve. "Our company is driven by our commitment to providing tailored, high-quality patient care to as many patients as possible."
Trulieve patients across Florida can choose from the largest selection of THC and CBD products available in a variety of consumption methods, including smokable flower, concentrates, edibles, capsules, syringes, tinctures, topical creams, vaporizers, and more. Patients have access to nationally-beloved brands such as Bellamy Brothers, Bhang, Binske, Blue River, Black Tuna, Love's Oven, O.pen, and Sunshine Cannabis, all available exclusively at Trulieve in Florida.
For more information, or to learn how to become a registered patient, please visit Trulieve.com and connect on Instagram or Facebook.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S. operating in 11 states, with leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. To learn more about Trulieve, visit Trulieve.com.
Cision View original content:https://www.prnewswire.com/news-releases/trulieve-expands-patient-access-to-medical-cannabis-with-eighth-tampa-area-dispensary-301449161.html
SOURCE Trulieve Cannabis Corp.
Media Contact: Teresa Coulter, Public Relations, +1 (850) 681-8530, tcoulter@vancorejones.com; Investor Contact: Christine Hersey, Director of Investor Relations, +1 (424) 202-0210, Christine.Hersey@Trulieve.com
A little more revenue in '22--->>> THE VALENS COMPANY ENTERS MANUFACTURING PARTNERSHIP WITH MTL CANNABIS FOR EXTRACTION AND MANUFACTURING OF PRE-ROLLS AND VAPES
https://thevalenscompany.com/press-releases/the-valens-company-enters-manufacturing-partnership-with-mtl-cannabis-for-extraction-and-manufacturing-of-pre-rolls-and-vapes/
KELOWNA, BC, Dec. 22, 2021 /CNW/ – The Valens Company Inc. (NASDAQ: VLNS) (TSX: VLNS) (the “Company” or “The Valens Company”), a leading manufacturer of cannabis products, announces it has entered into a manufacturing partnership with Montreal Cannabis Médical Inc. (“MTL” or “MTL Cannabis”) to provide manufacturing and extraction services for MTL’s pre-rolls and vapes.
Valens expects the contract to begin at the end of the first quarter of fiscal 2022.
MTL is a flower-first company committed to bringing craft cannabis to the masses through a five-step process that includes an award-winning hydroponic system, hang-drying, and hand-trimming. With industry-leading yields, MTL offers high-quality cannabis at a competitive price point. Since its adult-use market launch in October 2020, MTL Cannabis has emerged as one of Canada’s fastest-growing dried flower consumer brands, placing in the top five in dried flower sales in most provinces.
“MTL has demonstrated the kind of success, consistency and quality that The Valens Company looks for in a partner,” said Tyler Robson, CEO of The Valens Company. “We are excited to expand our presence with one of the fastest-growing and reputable flower consumer brands in Canada.”
“Valens not only has one of the broadest ranges of manufacturing capabilities but also shares the same commitment to consumers and quality that we do,” said Richard Clement, CEO of MTL Cannabis. “We look forward to working with Valens to expand our offering for consumers in a greater variety of formats.”
At Valens, it’s personal.
About The Valens Company
The Valens Company is a leading manufacturer of cannabis products with a mission to bring the benefits of cannabis to the world. The Company provides proprietary cannabis processing services, in addition to best-in-class product development, manufacturing, and commercialization of cannabis consumer packaged goods. The Valens Company’s high-quality products are formulated for the medical, health and wellness, and recreational consumer segments, and are offered across all cannabis product categories with a focus on quality and innovation. The Company also manufactures, distributes, and sells a wide range of CBD products in the United States through its subsidiary Green Roads, and distributes medicinal cannabis products to Australia through its subsidiary Valens Australia. In partnership with brand houses, consumer packaged goods companies and licensed cannabis producers around the globe, the Company continues to grow its diverse product portfolio in alignment with evolving cannabis consumer preferences in key markets. Through Valens Labs, the Company is setting the standard in cannabis testing and research and development with Canada’s only ISO17025 accredited analytical services lab, named The Centre of Excellence in Plant-Based Science by partner and scientific world leader Thermo Fisher Scientific. Discover more on The Valens Company and its subsidiaries at http://www.thevalenscompany.com.
About MTL
MTL Cannabis is a privately-owned Canadian Licence Holder located in Montreal, Quebec. As a flower-first company built for the modern street, MTL Cannabis is a 57,000 sq ft licensed facility with room to expand to 130,000 sq ft in the existing 2 buildings and possible expansion to over 300,000 sq ft. Under the existing footprint, the indoor facility uses proprietary hydroponic growing methodologies supported by handcrafted techniques to produce products that are truly craft for the masses. MTL Cannabis currently produces over 13,000 kgs annually, yielding over 2kg per light. With supply deals in nine Canadian provinces, the company consistently hits top 5 in dried flower sales. MTL is the recipient of the Grow Up Awards ‘Craft Grower of the Year’ and ‘Best Hydroponic System’ and KIND Magazine’s Budtenders Choice for ‘Sativa of the Year’ for its signature strain, Sage n’ Sour.
MTL Cannabis’ goal has been clear from the start, be the brand that brings the best of the street to the shelves by staying committed to the craft. Please visit http://www.mtlcannabis.ca/
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, that the potential benefits of the Consolidation, including the effect on the Company’s application to list its Common Shares on the NASDAQ, will not be achieved, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
SOURCE The Valens Company Inc.
For further information: Jeff Fallows, President, The Valens Company; Investor Relations, ir@thevalenscompany.com, 1 647.956.8254; KCSA Strategic Communications, Phil Carlson / Elizabeth Barker, VLNS@kcsa.com, 1 212.896.1233 / 1 212.896.1203; Media, KCSA Strategic Communications, Anne Donohoe, adonohoe@kcsa.com, 1 212.896.1265
MediPharm Labs Receives Award for CBD Brand of the Year
https://www.medipharmlabs.com/news/press-releases/detail/200/medipharm-labs-receives-award-for-cbd-brand-of-the-year
December 22, 2021
MediPharm Labs pharma-quality CBD dominant oil line has been awarded CBD Brand of the year by KIND Magazine.
MediPharm Labs’ CBD products have seen steady revenue growth and notoriety in 2021, including on national television on an episode of CBC Marketplace.
BARRIE, Ontario, Dec. 22, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has been awarded best CBD brand of the year by Kind Magazine.
“MediPharm Labs is honoured to be selected as CBD Brand of the Year. The MediPharm CBD SKUs lead our wellness line of products which are produced to a pharmaceutical quality standard in a GMP licensed facility,” said Bryan Howcroft, CEO, MediPharm Labs. “The award being voted by front line staff of cannabis retailers is a testament to our pharma-quality brand fulfilling wellness consumers’ needs.”
Kind Magazine is published across Canada and distributed in cannabis retail stores. The Kind Awards were determined by a panel of 235 frontline cannabis retail staff. MediPharm Labs has built a reputation for pharma-quality CBD, THC, and CBN oils, which consumers seek for wellness solutions. The advanced quality manufacturing process of MediPharm Labs was also featured on national television on CBC Marketplace as producers highlighted the pitfalls of the CBD black market and the advantages of licensed quality manufactures. The episode, The Truth About CBD, can be viewed online.
According to the Ontario Cannabis Store, Canada’s largest cannabis distributor, in the most recent quarter, CBD-dominant products were the second-fastest selling category, 135 times faster than the slowest selling products. This trend is replicated across the country and provides MediPharm Labs with near term revenue improvement opportunity. The average direct margin on MediPharm CBD oil SKUs is healthy making the expansion of these sales beneficial to positive gross margin.
The Company looks forward to further communicating new CBD and other wellness products to improve revenue from Canadian distribution as well as act as proof of concept for international distribution and large pharmaceutical and natural health product contract manufacturing services enabled by the Company’s unique GMP Drug Establishment and Natural Health Product manufacturing licenses.
Option Grant
The Company granted 1,000,000 stock options to its Chief Financial Officer, Greg Hunter, with an exercise price set at the close of business on December 17, 2021. Each option grant has a five-year term expiring December 17, 2026. The options vest in five equal instalments, the first of which vests immediately with the four other instalments vesting on the dates which are six, twelve, eighteen and twenty-four months from the grant date. The grants are subject to any necessary regulatory approvals.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing License for the extraction of natural cannabinoids.
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: fulfilling wellness consumers’ needs; trends regarding CBD dominant product sales; average direct margin; positive gross margin; new CBD and other wellness products; international distributions; and large pharmaceutical and natural health product contract manufacturing services. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4874975d-c7aa-4ab5-a8a6-d60e25967640
MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway
https://www.medipharmlabs.com/news/press-releases/detail/199/medipharm-labs-provides-operational-update-and-confirms
December 21, 2021
Strong cash balance and continued reduction of convertible debt to less than $500K.
Opportunities for optimization of the operating strategy between Australia and Canada as the Canadian Drug Establishment Licence (DEL) unlocks many manufacturing and supply chain pathways. These pathways will reduce infrastructure cost, improve delivery times, and increase customer satisfaction.
Delivery to five international medical cannabis markets including first deliveries of advanced GMP CBD isolate to traditional pharmaceutical companies.
TORONTO, Dec. 21, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on the significant strategic profitability improvement initiatives underway at the Company.
“Although the cannabis industry has seen a pull back in the capital markets, I remain extremely positive in my outlook for MediPharm Labs as it is a unique and well positioned organization. With a robust sales funnel, tangible opportunities to work more efficiently and reduce costs, and already recognized progress in improving our direct margin through strategic sourcing, we are on path to improvement,” said Bryan Howcroft, CEO, MediPharm Labs.
“In a very short period, the Board has seen improvements in organizational focus and decisiveness. Bryan has clearly come with positive energy, an ability to simplify strategy that enables execution, and tenacity to drive results. This leadership is exactly what we need to deliver on the improvements and growth we plan to achieve,” said Chris Taves, Chairman of the Board, MediPharm Labs.
2021 was a year of transition for MediPharm Labs and paved the strategic foundation for the future. The following highlights the Company’s focus areas on its path to profitability.
Strong Financial Foundation: Strong Cash Position with no Material Debt
MediPharm Labs continues to operate with a strong cash position and clean balance sheet. With the Company’s only debt agreement being a 2020 convertible debenture that holds a balance of less than $500K, down from an original balance of over $40M. This position paired with a robust plan to reduce overhead, operating expenses and general and administrative expenses gives MediPharm Labs longevity to execute on its sales contracts and pipeline. This strong financial position is especially important given the current capital markets conditions in the cannabis industry.
Pharmaceutical Business Development: Uniquely Placed for a Promising Market
MediPharm Labs is not an ordinary cannabis company. Being the only purpose-built facility in North America to receive a domestic GMP licence specifically for the extraction of natural cannabinoids, MediPharm Labs continues to use its Drug Establishment Licence to build its pharmaceutical business. There are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process and this business continues to develop with the approach of FDA patent challenges for generic forms of current drugs. Notwithstanding the longer pharmaceutical sales cycle of these products, MediPharm Labs has already shipped GMP CBD for development purposes to multiple established pharmaceutical companies.
The cannabis-based drug opportunity is predicted to be over $25 billion by 2025 according to Prohibition Partners. The sector has seen major progress in 2021, which started in February with the Jazz Pharmaceuticals’ $7.2 billion acquisition of GW Pharma, the UK based producer of natural CBD and THC based drugs. It continued in December with Pfizer’s $6.7 billion acquisition of Arena Pharmaceuticals, a drug development company with cannabis products in its pipeline.
Progress in International Medical Markets: Unlocking New Revenue Opportunities
In 2021, MediPharm Labs delivered medical cannabis products to five different countries providing its clients, including pharmaceutical and large cannabis companies, with a full product and supply chain solution so that they can focus on their end consumer. MediPharm Labs being one of the only white label providers in international markets has resulted in multiple contracts and filled the Company’s sales pipeline with opportunity that will be monetized as regulatory channels open. Projects like Brazilian product authorization will unlock new international revenue opportunities in 2022.
Adding multiple new customers to the Company’s international business has allowed for new volume-based buying that will improve gross margins on international business in the near term.
International cannabis markets continue to see the achievement of big milestones, for example the recent legalization in Malta and a new coalition government in Germany who have indicated cannabis legalization as part of their mandate. As more countries make legislative advances in cannabis, MediPharm Labs benefits through its experience of having existing international customers and supply channels.
Building a Successful Canadian Adult Use Business: Higher Quality Products and Growing Market Share
Although MediPharm Labs long-term focus has been international wellness and pharmaceutical markets, Canada offers the Company near-term positive margin and a product development testing ground. MediPharm Labs intention is to capitalize on opportunities to grow where it is strategically aligned.
“We have continued to improve our presence in the Canadian cannabis market. Led by premium high quality oil products, the Company has seen continued improvement in retail store listings. As an example of this progress, in Ontario, from Q1 2021 to Q3 2021 our market share in the oil category went from 4% to 8%, as reported by the Ontario Cannabis Store,” said Bryan Howcroft, CEO, MediPharm Labs.
MediPharm Labs premium cannabis oil has an average price of nearly double what the Company’s top competitors are selling for. This shows that consumers recognize the value in a higher quality product offering.
To expand in this category, MediPharm Labs will continue to focus on its premium portfolio sales in retail while driving innovation. The Company continues to launch unique oil SKUs with its new Cannabinol (CBN) with only trace amounts of THC oil launched in Q4 2021.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing License for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: optimization of operating strategy; reduced infrastructure costs; improved delivery times; increased customer satisfaction; positive outlook; unique and well positioned organization; working more efficiently; reducing costs; improved direct margin; being on the path to improvement; driving results; achieving improvements and growth; reducing overhead, operating expenses and general and administrative expenses gives; longevity; executing on sales contracts and pipeline; the value of the cannabis-based drug opportunity; monetizing opportunity as regulatory channels open; new international revenue opportunities in 2022; improved gross margins; legislative advances benefiting the Company; focus on the Company’s premium portfolio sales; near-term positive margin; driving innovation; and launching unique oil SKUs. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
Tilray to Announce Second Quarter Fiscal 2022 Financial Results on January 10, 2022
December 20, 2021 at 7:30 AM EST
https://ir.tilray.com/news-releases/news-release-details/tilray-announce-second-quarter-fiscal-2022-financial-results
Company to Also Host Fireside Chat at the 24th Annual ICR Conference on January 10, 2022
NEW YORK and LEAMINGTON, Ontario, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its second quarter fiscal 2022 ended November 30, 2021 before financial markets open on January 10, 2022.
Tilray executives will host a conference call and live audio webcast to discuss these results at 8:30 am Eastern Time, details of which are provided below.
Live Conference Call and Audio Webcast:
Date/Time: Monday, January 10, 2022 at 8:30 am Eastern Time.
Call-in Number: (877) 407-0792 from Canada and the U.S. or (201) 689-8263 from international locations. Please dial in at least 10 minutes prior to the start time.
A telephone replay will be available approximately two hours after the call concludes through January 26, 2022. To access the recording dial (844)-512-2921 and use the passcode 13725661.
Live Audio Webcast and Replay:
There will be a simultaneous, live webcast available on the Investors section of Tilray’s website at www.tilray.com. The webcast will also be archived.
Additionally, Tilray shareholders will be able to submit and upvote questions for the upcoming conference call to the executive team via shareholder Q&A platform Say Technologies.
To submit questions ahead of the conference call, please visit the Say platform (https://app.saytechnologies.com/tilray-2022-q2?filter=all&sort=num_shares). Tilray shareholders and brokers with Say can participate directly in their investing app or broker website. The Q&A platform for Tilray’s upcoming conference call on January 10, 2022, will remain open until 24 hours beforehand.
ICR Conference Participation
Irwin D Simon, Chairman and Chief Executive Officer, and Carl Merton, Chief Financial Officer, will also participate in a separate fireside chat discussion and hold investor meetings at the 24th Annual ICR Conference. Tilray's fireside chat discussion will be held on Monday, January 10, 2022 at 1:30 pm Eastern Time.
The live audio webcast will be accessible in the Events & Presentation section on the Company's Investor Relations website at https://ir.tilray.com/events-and-presentations/events. An archived replay of the webcast will also be available shortly after the live event has concluded.
About Tilray
Tilray Inc. is a leading global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people's lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation, and distribution, Tilray’s unprecedented production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and alcoholic beverages.
For more information about Tilray, Inc., visit: http://www.Tilray.com
Contacts
For media inquiries, please contact:
Berrin Noorata
news@tilray.com
For investor inquiries, please contact:
Raphael Gross 203-682-8253
Raphael.Gross@icrinc.com
SWEETWATER BREWING ACQUIRES GREEN FLASH BREWING AND ALPINE BEER CO BRANDS – PRESS RELEASE
DAN Beer News, SweetWater Brewing 0
(ATLANTA, GA) – SweetWater Brewing Company, LLC (“SweetWater”) today announced that it has acquired Green Flash and Alpine Beer, partnering up with the two iconic West Coast craft beer brands that boast award-winning brews as SweetWater continues its new market, portfolio, and innovation expansion.
SweetWater Green Flash Alpine
Both Alpine, known for its highly-rated Duet and Nelson brews, and Green Flash, the brewer of the iconic West Coast IPA, provide high-quality and highly-respected craft brew staples that seamlessly join SweetWater’s portfolio of flavorful and innovative craft brews and heady lifestyle, making this another perfect duet that will bring these brands to their highest potential.
“We’re excited to join forces with two phenomenal brands and brews in Alpine and Green Flash,” said Freddy Bensch, co-founder and CEO of SweetWater. “We have a lot of respect for both brands, which along with SweetWater have a passion for tasty brews and a great time. The West Coast lifestyle that is part of these brewery’s DNA perfectly aligns with our 420 lifestyle and SweetWater’s brand. We’re looking forward to keeping the legacy of these great brands intact, and bringing them back to prominence, furthering their potential, and bringing them to craft beer fans across the U.S.”
Green Flash has been crafting award-winning beers for nearly 20 years, including the original “West Coast IPA.” And Alpine, known as the “Home of Pure Hoppiness” with Nelson and Duet IPA, has been brewing world-class ales since ’99.
“As SweetWater continues to expand, alongside our new partners we’re looking forward to growing these iconic brands and strengthening operations to deliver some of the best tasting and highest-quality brews to all of our fans across the U.S. and around the world,” continued Bensch. “As we actively seek to acquire brands that embody the energy, brewing style, and lifestyle of SweetWater Brewery, we saw a partnership with Green Flash and Alpine Beer as a perfect fit. We are beyond stoked to welcome them to the SweetWater Family.”
As SweetWater continues its westward expansion, the brewery plans to immediately add twelve new positions along with a $2 million investment in its western markets, inclusive of the new Green Flash and Alpine addition to the business.
The deal marks a year of major expansions and partnerships, including the acquisition and opening of SweetWater’s Western US brewery, further westward expansion, the first extension of its iconic 420 flagship brew with SweetWater 420 Imperial IPA and becoming a full-service beverage alcohol supplier, introducing Oasis Lemonade, Golden Isles Hard Tea and SweetWater RIFF, the brewery’s first spirits-based ready-to-drink cocktails. Along with RIFF, SweetWater also collaborated with Broken Coast, two brands joined together under Sweetwater’s parent company Tilray, the world’s largest provider of cannabis, who acquired the brewery in November of 2020.
The Alpine and Green Flash brands and core brews will stay intact, along with plans to bring new and exciting future innovations to the highly-respected portfolio from each brand, whose cultures are a natural fit with SweetWater’s lifestyle and brewing credentials.
“Green Flash and Alpine are fantastic OG craft brands, backed up by incredibly-rated beers which is something SweetWater is both proud and eager to expand upon and broaden their reach across the US” states Brian Miesieski, Chief Marketing Officer. “We’re excited to link up and head out on an exciting new journey with our new brothers-in-beery-arms.”
This addition introduces the brewery to its furthest western market to date, following the opening of SweetWater’s second brewery location in Fort Collins, Colorado, which is now officially open to the public and set to begin production for distribution in early 2022. SweetWater’s award-winning lineup of year-round, seasonal, and specialty beers are now available in 38 states, plus Washington, D.C. wherever the fishin’s good.
###
About SweetWater Brewing Company:
SweetWater Brewing Company is an Atlanta-based craft brewery living by the motto “Don’t Float the Mainstream!” In 2020, SweetWater was acquired by Aphria Inc., now Tilray (Nasdaq: TLRY and TSX: TLRY), a leading global cannabis company inspiring and empowering the worldwide community to live their very best life. SweetWater Brewing Company celebrated 24 years of heady brews in 2021 and is the 11th largest craft brewery in the nation, according to Brewers Association. The award-winning lineup of year-round beers includes 420 Extra Pale Ale, H.A.Z.Y. IPA, 420 Imperial I.P.A., G13 IPA, High Light Lo-Cal Easy IPA, Goin’ Coastal IPA, Broken Coast Lager, SweetWater Oasis Premium Hard Seltzer, and Golden Isles Hard Iced Tea, and SweetWater RIFF RTD cocktails. Additionally, seasonal releases offer palate-pleasing variety, along with an experimental, one-time-only Dank Tank series, 420 Strain Series, and progressive barrel-aged styles in The Woodlands Project series.
SweetWater is passionate about protecting natural resources and habitats and is recognized for its contributions to environmental initiatives throughout its distribution footprint. Supporting the conservation of some of the nation’s most threatened rivers, streams and coastlines is a cause near and dear to the brewery, as clean water is also vital to the creation of their tasty brews.
SweetWater Brewing Company has two locations, with its flagship brewery and taphouse at 195 Ottley Drive in the heart of Atlanta, and its second location is now open in Fort Collins, Colorado at 1020 E Lincoln Ave. For more information about SweetWater Brewing Company, please visit www.sweetwaterbrew.com, follow SweetWater on Twitter/Instagram @sweetwaterbrew, and become a fan at facebook.com/sweetwaterbrew.
About Alpine:
Alpine Beer Company is an award-winning craft brewery founded in 1999, and is rated a top 50 brewery in the United States with highly-rated favorites including Nelson IPA and Duet IPA. In 2014, Alpine Beer Company merged with San Diego’s Green Flash Brewing Company, increasing production and distribution of its ales. For more information visit www.alpinebeerco.com
About Green Flash:
Green Flash is an award-winning, independently owned and operated craft brewery founded in 2002 to bring fresh ideas and a sense of adventure to craft beer. Green Flash delivers an eclectic lineup of specialty craft beers and distributes them throughout California and selected Southwestern and Northeastern U.S. markets. For more information, please visit www.greenflashbrew.com.
For SweetWater media inquiries, please contact Haley Filippone: pr@sweetwaterbrew.com
THE VALENS COMPANY ANNOUNCES TWO STRATEGIC AGREEMENTS WITH PMI MEXICO
• Valens to serve as exclusive supplier of CBD for PMI’s clinical trial, which will measure anti-inflammatory applications of medical-grade, nano-water emulsified CBD oil
• Valens will manufacture and distribute CBD infused and uninfused Predilife? prebiotic products for PMI throughout the country
KELOWNA, BC, Dec. 21, 2021 /CNW/ – The Valens Company Inc. (TSX: VLNS) (NASDAQ: VLNS) (the “Company,” “The Valens Company” or “Valens”), a leading manufacturer of cannabis products, announced today two agreements with PMI Mexico, a subsidiary of Merger Group, one of the main drug suppliers of the Mexican government.
Under the first agreement, Valens will supply CBD for PMI’s ongoing pharmacokinetic (PK) stage medical trials, which are focused on anti-inflammatory applications of medical-grade, nano-water emulsified CBD oil. The clinical trial has already been approved by The Medical Ethics Board of Mexico. The clinical trial, which is set to begin once Valens shipments arrive in Q1 of 2022, will be conducted across private hospitals in Mexico. At the conclusion of the trial, Valens will be the sole manufacturer and global distributor in collaboration with PMI.
Under the second agreement, Valens will manufacture and distribute CBD-infused and uninfused Predilife? products globally while PMI will be responsible for distribution of the Predilife? products in Mexico.
Predilife is an agave-based prebiotic powder that has been submitted as a drug master file” (DMF) to the FDA. Valens will manufacture the products at its Green Roads facility in Florida, where it will be infused with CBD as required and then packaged and distributed through Valens’ third-party supplier channels across Asia, U.S., Latin America and Mexico. The formulation will be offered in both powder and liquid sachets, initially for human consumption, with animal variations planned for the second half of 2022.
“The relationship we have built with PMI Mexico marks an important milestone for Valens’ international expansion and the beginning of our Central and Latin America strategy,” said Tyler Robson, CEO, Chair & Co-founder of The Valens Company.
“Predilife has significant and unique versatility in terms of reach and market potential given it can be consumed infused or uninfused with CBD. This enables unimpeded distribution of the product regardless of local cannabis regulations, providing Valens access to several international markets. This agreement diversifies our global strategy and increases our revenue streams through creative, non-traditional strategies that separate us from our peers.”
Gustavo Bustillo PhD, Scientific Director of PMI said, “In Valens we found a technological partner that was capable of providing us not only the required quality but also the technical support and necessary documents needed to comply with pharmaceutical regulations. We look forward to initiating our commercial relationship and watching it expand globally over the coming years.”
At Valens, it’s Personal.
About The Valens Company
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company’s investor deck can be found specifically at https://thevalenscompany.com/investors/.
About Merger Group
Merger Group, based in Newark, Delaware is a pioneer in developing drugs and supplements with over 20 years of experience across the pharmaceutical industry. Merger Group is dedicated to the research, innovation and development of both medicine and natural and herbal products which can help progress the lifestyles of its users by improving their health and well-being. PMI Mexico, a division of Merger Group, is a subsidiary dedicated to the research, clinical studies, review and integration of technical documentation to obtain health records, coordination of logistics and import permits.
Notice regarding Forward Looking Statements
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “forecasts”, “future”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “should”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, future outcomes of transactions, economic conditions, and anticipated courses of action. Investors and other parties are advised that there is not necessarily any correlation between the number of SKUs manufactured and shipped and revenue and profit, and undue reliance should not be placed on such information.
The risks and uncertainties that may affect forward-looking statements include, among others, whether the Company will be able to fulfill all of listing requirements of the Nasdaq, Canadian regulatory risk, Australian regulatory risk, U.S. regulatory risk, U.S. border crossing and travel bans, the uncertainties, effects of and responses to the COVID-19 pandemic, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, limited operating history, vulnerability to rising energy costs, unfavorable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
SOURCE The Valens Company Inc.
For further information: Visit: https://merger-group.com/ For more information please contact: Mauricio Villanueva CEO Merger group General Manager; PMI Maribel rubio direcciongral@pmi1210.com 52 33 16 68 15 19 Scientific Director; Gustavo Bustillo Ph.D. gbustillo@pmi1210.com 52 33 38 14 20 31; For further information, please contact: Jeff Fallows, President, The Valens Company; Investor Relations, ir@thevalenscompany.com, 1 647.956.8254; KCSA Strategic Communications, Phil Carlson, valens@kcsa.com, 1 212.896.1233
RELATED LINKS
https://thevalenscompany.com/
ABOUT THE VALENS COMPANY
The Valens Company is a global leader in the end-to-end development and manufacturing of innovative, cannabinoid-based products. The Valens Company is focused on being the partner of choice for leading Canadian and international cannabis brands by providing best-in-class, proprietary services including CO2, ethanol, hydrocarbon, solvent-less and terpene extraction, analytical testing, formulation and product development and custom manufacturing. Valens is the largest third-party extraction company in Canada with an annual capacity of 425,000 kg of dried cannabis and hemp biomass at our purpose-built facility in Kelowna, British Columbia which is in the process of becoming European Union (EU) Good Manufacturing Practices (GMP) compliant. The Valens Company currently offers a wide range of product formats, including tinctures, two-piece caps, soft gels, oral sprays and vape pens as well as beverages, concentrates, topicals, edibles, injectables, natural health products and has a strong pipeline of next-generation products in development for future release. Finally, The Valens Company’s wholly-owned subsidiary Valens Labs is a Health Canada licensed ISO 17025 accredited cannabis testing lab providing sector-leading analytical services and has partnered with Thermo Fisher Scientific to develop a Centre of Excellence in Plant-Based Science. For more information, please visit https://thevalenscompany.com. The Valens Company’s investor deck can be found specifically at https://thevalenscompany.com/investors/.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Jeff Fallows
The Valens Company
Investor Relations
ir@thevalenscompany.com
1 647.956.8254
KCSA Strategic Communications
Phil Carlson / Elizabeth Barker
VLNS@kcsa.com
1 212.896.1233 / 1 212.896.1203
Media
KCSA Strategic Communications
Anne Donohoe
adonohoe@kcsa.com
1 212.896.1265
NOTICE REGARDING FORWARD LOOKING STATEMENTS
All information included in this press release, including any information as to the future financial or operating performance and other statements of The Valens Company that express management’s expectations or estimates of future performance, other than statements of historical fact, constitute forward-looking information or forward-looking statements within the meaning of applicable securities laws and are based on expectations, estimates and projections as of the date hereof. Forward-looking statements are included for the purpose of providing information about management’s current expectations and plans relating to the future. Wherever possible, words such as “plans”, “expects”, “scheduled”, “trends”, “indications”, “potential”, “estimates”, “predicts”, “anticipate”, “to establish”, “believe”, “intend”, “ability to”, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will”, or are “likely” to be taken, occur or be achieved, or the negative of these words or other variations thereof, have been used to identify such forward-looking information. Specific forward-looking statements include, without limitation, all disclosure regarding future results of operations, economic conditions and anticipated courses of action.
The risks and uncertainties that may affect forward-looking statements include, among others, regulatory risk, United States border crossing and travel bans, reliance on licenses, expansion of facilities, competition, dependence on supply of cannabis and reliance on other key inputs, dependence on senior management and key personnel, general business risk and liability, regulation of the cannabis industry, change in laws, regulations and guidelines, compliance with laws, reliance on a single facility, limited operating history, vulnerability to rising energy costs, unfavourable publicity or consumer perception, product liability, risks related to intellectual property, product recalls, difficulties with forecasts, management of growth and litigation, many of which are beyond the control of The Valens Company. For a more comprehensive discussion of the risks faced by The Valens Company, and which may cause the actual financial results, performance or achievements of The Valens Company to be materially different from estimated future results, performance or achievements expressed or implied by forward-looking information or forward-looking statements, please refer to The Valens Company’s latest Annual Information Form filed with Canadian securities regulatory authorities at www.sedar.com or on The Valens Company’s website at www.thevalenscompany.com. The risks described in such Annual Information Form are hereby incorporated by reference herein. Although the forward-looking statements contained herein reflect management’s current beliefs and reasonable assumptions based upon information available to management as of the date hereof, The Valens Company cannot be certain that actual results will be consistent with such forward-looking information. The Valens Company cautions you not to place undue reliance upon any such forward-looking statements. The Valens Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law. Nothing herein should be construed as either an offer to sell or a solicitation to buy or sell securities of The Valens Company.
CVS Health: Upside Remains
Dec. 15, 2021 9:14 AM ETCVS Health Corporation (CVS)WBA, AMZN36
The terms are steep and the maturity date is in a blink of an eye.
PI Financial Reiterates FFLWF's $20 Price Target Following Q3 Results <<<--- Is this a load of BS?
December 15, 2021 3:39 PM
INDIVA SIGNS EXCLUSIVE LICENSING AND MANUFACTURING AGREEMENT WITH GRÖN
INDIVA TO BRING INNOVATIVE EDIBLES BRAND PORTFOLIO TO CANADA
https://www.indiva.com/press-releases/releases-2021/indiva-signs-exclusive-licensing-and-manufacturing-agreement-with-gron/
LONDON, Ontario – December 15, 2021: Indiva Limited (the “Company” or “Indiva”) (TSXV:NDVA) (OTCQX:NDVAF), the leading Canadian producer of cannabis edibles, is pleased to announce that it has entered into a Licensing and Manufacturing Agreement with Oregon-based Grön to bring its innovative and fun edibles brand portfolio to Canada. Following on Indiva’s success producing and distributing the top selling chocolates and gummies in Canada, the launch of Grön products in Canada will expand Indiva’s edible portfolio to include products with thoughtful, unique minor cannabinoid ratio combinations and form factors. The initial term of the agreement is for five years, automatically renewing for three additional five-year terms.
Founded by Christine Smith, the woman-led and owned edible brand Grön (pronounced “grewn”) is based in Portland, Oregon, and is one of Oregon’s leading producers and fastest-growing distributors of cannabis edibles. Grön’s edibles portfolio includes candy-coated chocolate ‘Pips’, chocolate bars, gelatin gummy ‘Pearls’ and other novel edible products. Grön currently manufactures and distributes its products across four US states, where legally permissible to do so under applicable state laws, and distributes its CBD-infused products into international markets.
“We are delighted to partner with Grön to bring their innovative, original, high-quality edible products to the Canadian market,” said Niel Marotta, CEO of Indiva. “Indiva remains committed to growing its top-line and market share organically in Canada by bringing products to market that delight our customers, while expanding the selection of legal cannabis edibles in Canada. This agreement will allow Indiva to do just that, with new products which are unique to the Canadian market and complementary to our existing portfolio of cannabis edibles.”
“We are excited to partner with the Indiva team to bring what we believe are the best tasting edibles in the market today. Their commitment to product consistency and industry support gives us confidence that they will be exceptional stewards of the Grön brand. Grön’s cannabis-infused edibles are the perfect addition to the Canada adult-use cannabis market, bringing the ‘Edibles 2.0’ to the community through our innovative effect-driven cannabinoid ratios, deliciously refreshing gummy and chocolate flavors, all made with high quality ingredients,” said Christine Smith, Founder and CEO of Grön.
Indiva intends to begin production of Grön products in Canada as soon as possible, with initial deliveries to provincial wholesalers targeted for late Q2 2022.
ABOUT GRÖN
Grön is a women-led multi-state producer of the best tasting adult-use cannabis-infused edibles. The passionate team of seasoned executives, chocolatiers, and confectioners come from all over the world to create something beautifully delicious for you. Their ingredients are organic, single-origin, Fair Trade Certified, and locally sourced whenever possible. Product offerings in US markets include cannabis-infused chocolate, Sugar-Coated Pearls, Mega Pearls, Candy-Coated Chocolate Pips, as well as Hemp CBD and adaptogen-infused chocolate, vegan fruit chews, tinctures, and skincare. Since inception, they’ve led the cannabis edibles category in the markets in which they operate with a vast selection of thoughtfully formulated products. Though Grön was founded in 2015 producing artisan cannabis-infused chocolate, product innovation continues to shape their offerings in markets hungry for something new. Grön cannabis edibles are available in Arizona, Nevada, Oklahoma, and Oregon, with multiple new markets anticipated to be added in 2022. Connect with Grön on Instagram, LinkedIn, Twitter, or on their website — eatgron.com.
ABOUT INDIVA
Indiva sets the standard for quality and innovation in cannabis. As a Canadian licensed producer, Indiva produces and distributes award-winning cannabis products including Bhang® Chocolate, Wana™ Sour Gummies, Slow Ride Bakery Cookies, Jewels Chewable Tablets, Ruby® Cannabis Sugar, Sapphire™ Cannabis Salt, as well as capsules, pre-rolls and premium flower under the INDIVA and Artisan Batch brands. Click here to connect with Indiva on LinkedIn, Instagram, Twitter and Facebook, and here to find more information on the Company and its products.
CONTACTS
INVESTOR CONTACT
Anthony Simone
Phone: 416-881-5154
Email: ir@indiva.com
DISCLAIMER AND READER ADVISORY
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) has in any way passed upon the merits of the contents of this press release and neither of the foregoing entities accepts responsibility for the adequacy or accuracy of this release or has in any way approved or disapproved of the contents of this press release.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the parties’ current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the Company’s future operations, future results, future product offerings and compliance with applicable regulations. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the parties. The material factors and assumptions include the parties being able to maintain the necessary regulatory and other third parties’ approvals and licensing and other risks associated with regulated entities in the cannabis industry, future sales, the demand for the Company’s products and cannabis products generally and the continued operations of the Company in the ordinary course. The forward-looking information contained in this release is made as of the date hereof and the parties are not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities law.
Green Thumb Industries to Open GreenStar Herbals Chelsea in Massachusetts, Its 68th Retail Location in the Nation, on December 15
DECEMBER 14, 2021
https://investors.gtigrows.com/investors/news-and-events/press-releases/press-release-details/2021/Green-Thumb-Industries-to-Open-GreenStar-Herbals-Chelsea-in-Massachusetts-Its-68th-Retail-Location-in-the-Nation-on-December-15/default.aspx
CHICAGO and CHELSEA, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. (GTI) (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer packaged goods company and owner of Rise dispensaries, today announced it will open GreenStar Herbals Chelsea in Massachusetts on Wednesday, December 15, 2021. The store will be rebranded to Rise in 2022. Profits from the first day of sales will be donated to La Colaborativa, an organization committed to empowering Latinx immigrants to enhance the social and economic health of the community and its people.
“Since entering Massachusetts in 2018, we have expanded our retail footprint to six stores, the maximum amount permitted by the state,” said Green Thumb Founder and Chief Executive Officer Ben Kovler. “We are excited to open a new store in Chelsea which will allow us to serve more consumers in the greater Boston area. We are also proud to donate our first day profits to La Colaborativa, who is doing important work supporting Greater Boston’s Latinx community by providing food distribution and housing, legal aid, education and job training.”
Dinanyili Paulino, Chief Operations Officer of La Colaborativa said: “La Colaborativa is excited to welcome Green Thumb to the Chelsea community and we are very appreciative of their donation. This donation will help us continue our mission of making a positive impact on Greater Boston’s Latinx community through citizenship support, educational programs and food distribution services.”
In addition to the new store in Chelsea, the Company owns and operates adult-use retail stores in Dracut and Maynard, along with medical-use retail stores in Amherst, Boston and West Springfield. The Chelsea location is less than three miles from Boston-Logan International Airport and one mile from Encore Boston Harbor.
Green Thumb’s branded products, including RYTHM premium flower and vapes; Dogwalkers brand pre-roll joints; and incredibles gummies, chocolates and tarts, are produced in the Commonwealth and available at licensed cannabis dispensaries across Massachusetts. The company recently launched Good Green, a line of cannabis products that reflects Green Thumb’s mission to promote change by making impactful investments in organizations working to correct the harms created by the War on Drugs. The second round of Good Green grant applications is now open to 501c3 organizations until January 12, 2022 at www.good.green.
Green Thumb began serving medical patients in Massachusetts in 2018 and has two operational cultivation and production facilities in Holyoke and Clinton that continue to support the growing consumer demand for high-quality cannabis.
GreenStar Herbals Chelsea is located at 200 Beacham Street in Chelsea. Regular hours are Monday through Saturday from 9 a.m. to 10 p.m. and Sunday from 10 a.m. to 8 p.m. Visit www.greenstarherb.com for more information.
About Green Thumb Industries:
Green Thumb Industries Inc. (“Green Thumb”), a national cannabis consumer packaged goods company and retailer, promotes well-being through the power of cannabis while giving back to the communities in which it serves. Green Thumb manufactures and distributes a portfolio of branded cannabis products including Beboe, Dogwalkers, Doctor Solomon’s, Good Green, incredibles and RYTHM. The company also owns and operates rapidly growing national retail cannabis stores called Rise. Headquartered in Chicago, Illinois, Green Thumb has 16 manufacturing facilities, 68 open retail locations and operations across 14 U.S. markets. Established in 2014, Green Thumb employs approximately 3,500 people and serves millions of patients and customers each year. The company was named to Crain’s Fast 50 list in 2021 and a Best Workplace by MG Retailer magazine in 2018, 2019 and 2021. More information is available at www.GTIgrows.com.
See red for a bad stat--->>>FIRE & FLOWER ANNOUNCES FISCAL THIRD QUARTER 2021 FINANCIAL AND OPERATIONAL RESULTS
DECEMBER, 14, 2021
i.e. like a house closing.
CURALEAF ANNOUNCES $425 MILLION PRIVATE PLACEMENT OF 8% SENIOR SECURED NOTES DUE 2026
News Release Issued: Dec 13, 2021 (4:05pm EST)
To view this release online and get more information about Curaleaf Investor Relations visit: https://ir.curaleaf.com/2021-12-13-CURALEAF-ANNOUNCES-425-MILLION-PRIVATE-PLACEMENT-OF-8-SENIOR-SECURED-NOTES-DUE-2026
WAKEFIELD, Mass., Dec. 13, 2021 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, today announced that it has received commitments for a private placement of 8.0% Senior Secured Notes due 2026 (the "Notes") for aggregate gross proceeds of US$425 million (the "Offering").
The Notes, which will be issued at 100% of face value, will be senior secured obligations of the Company and will bear interest at a rate of 8.0% per annum, payable semi-annually in equal installments until the maturity date, unless earlier redeemed or repurchased. The Notes will be governed by a trust indenture to be entered into on closing of the Offering (the "Indenture"). The Indenture enables the Company to issue additional notes on an ongoing basis as needed, subject to maintaining leverage ratios and complying with the other terms and conditions of the Indenture. In addition, the Indenture permits up to an additional US$200 million of senior bank financing. Curaleaf intends to use the net proceeds from the Offering to refinance existing indebtedness, for working capital, and to pay transaction fees and expenses. The Notes will mature on December 15, 2026. The Offering is expected to close on December 15, 2021, subject to customary closing conditions.
"We are pleased to announce what we believe is the largest debt financing of any publicly-traded MSO to date," said Joseph Bayern, Chief Executive Officer of Curaleaf. "This offering will allow us to refinance our existing debt at a materially lower interest rate and provides us with additional financial flexibility to execute our strategic growth initiatives. While this initial offering provides more than enough liquidity to refinance our existing debt and meet current needs, the new Indenture provides us a new degree of flexibility to raise debt financing to ensure we have ample liquidity to meet our needs now and into the future."
Seaport Global Securities LLC and Canaccord Genuity Corp. (the "Agents") acted as placement agents for the Notes in the United States and Canada, respectively.
The Notes are being offered on a private placement basis in certain provinces and territories of Canada pursuant to applicable exemptions from the prospectus requirements of Canadian securities laws. The Notes may also be sold in the United States to or for the account or benefit of "U.S. persons" (as defined in the United States Securities Act of 1933, as amended (the "U.S. Securities Act")), on a private placement basis to "qualified institutional buyers" and "accredited investors" pursuant to an exemption from the registration requirements of the U.S. Securities Act, and in such jurisdictions outside of Canada and the United States as may be agreed upon by the Agents and the Company, in each case in accordance with applicable laws. The Notes to be issued will be subject to a customary four-month hold period under Canadian securities laws.
No securities regulatory authority has either approved or disapproved of the contents of this news release. The Notes have not been and will not be registered under the U.S. Securities Act or any state securities laws. Accordingly, the Notes may not be offered or sold within the United States or to or for the account or benefit of "U.S. persons" unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.
About Curaleaf Holdings
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is a leading international provider of consumer products in cannabis with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. In the United States, Curaleaf currently operates in 23 states with 113 dispensaries, 25 cultivation sites, and employs over 5,200 team members. Curaleaf International is the largest vertically integrated cannabis company in Europe with a unique supply and distribution network throughout the European market, bringing together pioneering science and research with cutting-edge cultivation, extraction and production. Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit https://ir.curaleaf.com.
Curaleaf IR Twitter Account: https://twitter.com/Curaleaf_IR
Investor Toolkit: https://ir.curaleaf.com/investor-toolkit
Investor Relations Website: https://ir.curaleaf.com/
Forward Looking Statements
This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward–looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects", "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward–looking statements and information concerning the intended use of the net proceeds from the Offering. Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed?April 28, 2021, which is available under the Company's SEDAR profile at?http://www.sedar.com, and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
Investor Contact:
Curaleaf Holdings, Inc.
Carlos Madrazo, SVP Head of IR & Capital Markets
IR@curaleaf.com
Media Contact:
Curaleaf Holdings, Inc.
Tracy Brady, VP Corporate Communications
Media@curaleaf.com
SOURCE Curaleaf Holdings, Inc.
SweetWater Brewing to open in former Red Truck space this month
By: Erin Udell
https://www.coloradoan.com/story/life/food/2021/12/10/fort-collins-breweries-sweetwater-announces-fort-collins-brewery-debut-date/6457787001/
Fort Collins Coloradoan
Atlanta-based SweetWater Brewing Co. will open its new Fort Collins brewery to the public on Dec. 18, 2021 — taking over Red Truck Brewing Company's former home at 1020 E Lincoln Ave. in Fort Collins.
A red truck has officially been replaced by a rainbow trout on Fort Collins' brewery row.
Atlanta-based SweetWater Brewing Co. will open its new Fort Collins brewery to the public Dec. 18 — taking over Red Truck Brewing Company's former home at 1020 E Lincoln Ave.
SweetWater Brewing acquired the Fort Collins brewery this summer, squelching speculation over Red Truck's fate in Fort Collins following more than a year-long taproom closure that started with the onset of the COVID-19 pandemic in March 2020.
The sale also marked a big step for SweetWater Brewing's planned expansion into Colorado, which also includes the opening of SweetWater Mountain Taphouse in Denver International Airport.
Fort Collins' former Red Truck space — which comes in at a whopping 32,450 square feet — underwent an extensive renovation of its brewing, packaging and taproom areas ahead of its planned Dec. 18 SweetWater Brewing debut.
One brewery opens, another closes:McClellan's Brewing Co. closes after 6 years, citing pandemic and inflation
SweetWater Brewing co-founders Freddy Bensch and Kevin McNerney both started their brewing careers washing kegs for Boulder Brewing Co. in 1992. The University of Colorado students ultimately joined forces again in Georgia when they opened SweetWater's original brewery in west Atlanta in 1997. McNerney resigned from the brewing company in 2008.
The brewery, which is known for its "raging 420 festival" each spring, embraces cannabis culture and the great outdoors. A rainbow trout is included in the brewery's logo, and a statue of one has been installed outside of its Fort Collins brewery.
Atlanta-based SweetWater Brewing Co. will open its new Fort Collins brewery to the public on Dec. 18, 2021 — taking over Red Truck Brewing Company's former home at 1020 E Lincoln Ave. in Fort Collins.
Visit Coloradoan.com for upcoming coverage from the Coloradoan on SweetWater Brewing Company's arrival in Fort Collins.
Erin Udell reports on news, culture, history and more for the Coloradoan. Contact her at ErinUdell@coloradoan.com. The only way she can keep doing what she does is with your support. If you subscribe, thank you. If not, sign up for a digital subscription to the Coloradoan today.
I hope so. I own a lot of shares and rode this all the way down.
At the slightest inkling of new life I will average all the way down.
Looking back on this, the BoD's action is exactly what you would hope for; a failure needs to be fired and replaced. Too bad it wasn't a complete sweep.
If you make it to college and keep failing all of the tests, the school kicks you out.
A responsible BoD can act no different. Failed management had to be swept out.
It's too bad it didn't happen sooner. Keeping legacy people around who are directly responsible for this failure is a mistake.
There may not be enough available money to recover from the devastation.
MediPharm Labs Announces Changes to Board of Directors
https://www.medipharmlabs.com/news/press-releases/detail/198/medipharm-labs-announces-changes-to-board-of-directors
December 07, 2021
BARRIE, Ontario, Dec. 07, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce changes to its Board of Directors (the “Board”).
Effectively immediately, Pat McCutcheon, Warren Everitt and Keith Strachan will be resigning from the Board. The change is being made as a next step in the Company’s transformation to an operating pharmaceutical cannabis manufacturing company, maturing beyond the founder-lead phase of the business.
“I would like to thank Pat, Warren and Keith for their vision and execution as founders of MediPharm Labs,” said Chris Taves, Chairman, MediPharm Labs. “Accomplishments like the first non-cultivation processing license in Canada, a fully functional GMP facility in Australia and the only domestic GMP license in North America for the extraction of natural cannabinoids, could not have been achieved without the vision and foresight of these leaders. We look forward to Warren and Keith’s continued involvement in management of the Company and Pat’s continued support as a major long-term shareholder.”
The Board is now composed entirely of Independent Directors with Bryan Howcroft, MediPharm Labs’ new CEO, being the only Executive Director. With MediPharm Labs’ strong cash position, the Board will oversee the Company’s execution of its global pharmaceutical cannabinoid strategy. The Board now consists of:
Chris Taves, Chairman
Bryan Howcroft, CEO
Chris Halyk
Shelley Martin
Miriam McDonald
Dr. Paul Tam
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm Labs formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a domestic Good Manufacturing License for the extraction of natural cannabinoids. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates.
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: transformation to an operating pharmaceutical cannabis manufacturing company; maturing beyond the founder-lead phase of the business; the Company’s strong cash position; and execution of the Company’s global pharmaceutical cannabinoid strategy. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.
For further information, please contact:
MediPharm Labs Investor Relations
Telephone: +1 416.913.7425 ext. 1525
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
Primary Logo
Source: MediPharm Labs Corp.
Released December 7, 2021
Cresco Labs Closes Acquisition of Pennsylvania Vertically Integrated Clinical Registrant, Laurel Harvest
December 10, 2021
https://investors.crescolabs.com/investors/press-releases/press-release-details/2021/Cresco-Labs-Closes-Acquisition-of-Pennsylvania-Vertically-Integrated-Clinical-Registrant-Laurel-Harvest/default.aspx
CHICAGO--(BUSINESS WIRE)-- Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the closing of the Company’s previously announced acquisition of Laurel Harvest Labs, LLC (“Laurel Harvest” or the “Transaction”). Laurel Harvest is a Pennsylvania Clinical Registrant.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211210005044/en/
Transaction Highlights
Approximately 52,000 sq. ft. of indoor grow/processing space
Foundation for an additional 52,000 sq. ft. of indoor cultivation space
One operational dispensary in Montgomeryville
A second dispensary in Scranton is currently under construction
Ability to open an additional four dispensaries throughout the state
“Between the acquisition of Laurel Harvest and the previously closed Cure Penn acquisition, we are executing our strategy of strategic breadth and depth, focused on the most important states, and positioning ourselves to capitalize on the eventual expansion of the cannabis program in Pennsylvania,” said Charlie Bachtell, Cresco Labs’ CEO & Co-founder. “We are tailoring our strategy to the unique dynamics of each state to maintain our leading market position and increase profitability. It is imperative for us to maximize our retail presence and add a second cultivation facility to optimize product quality, assortment and accessibility to maintain the number one wholesale market share in the state1. We’re very excited to further develop the research platform with Temple University as a key component of our mission to normalize and professionalize the industry – a responsible industry creates a respectable industry which, in turn, creates a robust cannabis industry.”
Laurel Harvest Clinical Registrant Highlights
One of eight original Chapter 20 licenses in Pennsylvania
Academic clinical research partnership with Lewis Katz School of Medicine at Temple University
Six current ongoing cannabis research studies
About Cresco Labs Inc.
Cresco Labs is one of the largest vertically integrated multistate cannabis operators in the United States, with a mission to normalize and professionalize the cannabis industry. Employing a consumer-packaged goods (“CPG”) approach, Cresco Labs is the largest wholesaler of branded cannabis products in the U.S. Its brands are designed to meet the needs of all consumer segments and comprised of some of the most recognized and trusted national brands including Cresco, High Supply, Mindy's Edibles, Good News, Remedi, Wonder Wellness Co. and FloraCal Farms. Sunnyside, Cresco Labs’ national dispensary brand, is a wellness-focused retailer created to build trust, education and convenience for both existing and new cannabis consumers. Recognizing that the cannabis industry is poised to become one of the leading job creators in the country, Cresco Labs operates the industry’s largest Social Equity and Educational Development initiative, SEED, which was established to ensure that all members of society have the skills, knowledge and opportunity to work and own businesses in the cannabis industry. Learn more about Cresco Labs at www.crescolabs.com.
Forward Looking Statements
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as, ‘may,’ ‘will,’ ‘should,’ ‘could,’ ‘would,’ ‘expects,’ ‘plans,’ ‘anticipates,’ ‘believes,’ ‘estimates,’ ‘projects,’ ‘predicts,’ ‘potential’ or ‘continue’ or the negative of those forms or other comparable terms. The Company’s forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under “Risk Factors” in the Company’s Annual Information Form for the year ended December 31, 2020 filed on March 26, 2021, and other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company’s forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs’ shares, nor as to the Company’s financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company’s forward-looking statements contained herein, whether as a result of new information, any future event or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
____________________
1 Source: Headset
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005044/en/
Media:
Jason Erkes, Cresco Labs
Chief Communications Officer
press@crescolabs.com
Investors:
investors@crescolabs.com
For general Cresco Labs inquiries:
312-929-0993
info@crescolabs.com
Source: Cresco Labs
Trulieve Announces Grand Opening of Okeechobee Dispensary
December 8, 2021 at 9:00 AM EST